FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including an antibody to B7-H4 or its antigen-binding fragment, a DNA molecule encoding the antibody or its antigen-binding fragment, an expression vector containing a DNA molecule, a host cell for expressing an antibody to B7-H4 or its antigen-binding fragment, a method for producing an antibody including culturing the host cell and isolating the antibody, a pharmaceutical composition for the treatment of B7-H4-mediated diseases or conditions, containing an antibody to B7-H4 or its antigen-binding fragment, a detection reagent designed for immunodetection or determination of B7-H4, a diagnostic tool for diagnosing B7-H4 mediated diseases or conditions; and the use of an anti-B7-H4 antibody or antigen-binding fragment or pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a B7-H4 mediated disease or condition.
EFFECT: invention expands the arsenal of agents that bind to B7-H4.
23 cl, 4 dwg, 23 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
| ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| FUNCTION PROTEIN AND ITS USE | 2019 |
|
RU2800923C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
